The negative FDA Oncologic Drugs Advisory Committee review of Aveo Pharmaceuticals Inc.’s renal cell carcinoma drug tivozanib should serve as a cautionary tale for pharmaceutical companies looking overseas to seed their clinical trials.
Not only must sponsors ensure that clinical trials reflect U.S. standard of care, they also must ensure that post-trial treatments...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?